PTEN and triple-negative breast carcinoma: In the LOTUS trial, which evaluated the efficacy of the AKT inhibitor ipatasertib combined with paclitaxel in patients with metastatic triple-negative breast cancer, patients with PTEN-low tumors did not experience significant benefits, indicating potential resistance to AKT inhibition in the context of PTEN loss (78).